Eli Lilly’s Retatrutide Shows ~30% Weight Loss in Phase 3 Trial
Positive topline results from the TRIUMPH‑1 Phase 3 obesity trial show Eli Lilly’s retatrutide delivering an average 28‑30% weight loss over 80‑104 weeks at the 12 mg dose, with 45% of participants losing over 30% and notable cardiometabolic improvements, positioning the drug as a likely blockbuster after Zepbound.